Orgenesis (NASDAQ:ORGS – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.
Insider & Institutional Ownership
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Orgenesis and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orgenesis | -3,827.81% | N/A | -130.18% |
| Roivant Sciences | -119.54% | -14.05% | -12.81% |
Volatility & Risk
Earnings & Valuation
This table compares Orgenesis and Roivant Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orgenesis | $662,000.00 | 25.01 | -$55.36 million | N/A | N/A |
| Roivant Sciences | $122.59 million | 60.65 | $4.35 billion | ($0.15) | -69.47 |
Roivant Sciences has higher revenue and earnings than Orgenesis.
Analyst Ratings
This is a summary of recent ratings and target prices for Orgenesis and Roivant Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orgenesis | 0 | 0 | 0 | 0 | 0.00 |
| Roivant Sciences | 0 | 1 | 5 | 1 | 3.00 |
Roivant Sciences has a consensus price target of $18.08, indicating a potential upside of 73.54%. Given Roivant Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Orgenesis.
Summary
Roivant Sciences beats Orgenesis on 12 of the 13 factors compared between the two stocks.
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
